Table 2.
The characteristics of included studies with a diagnostic test accuracy analysis
| ID | Sample size | Age | SA device | FEV1 | SA test | Cut-off | TP | FN | FP | TN | Sen. % | Spc. % | Diagnosis criteria |
| Li et al27 China Cross-sectional |
Asthma 561 Control 205 |
50.5 (18.8)* | MasterLab-IOS | NR | R5 X35 |
NR | 404 297 |
157 264 |
80 49 |
125 156 |
72 53 |
61 76 |
ATS guidelines |
| Nikkhah et al28 Iran Cross-sectional |
Asthma 87 Control 87 |
41.4 (15.5) 37.6 (17.8) |
MasterScreen-IOS | 2.2 (0.6) L 3.2 (0.9) L |
R5 X5 |
>0.51 ≤−0.2 |
60 36 |
27 51 |
12 8 |
75 79 |
69 41 |
86 91 |
GINA 2008 |
| Iartsev29 Russia Cross-sectional |
1. Asthma 209 2. Asthma 75 3. Asthma 81 Control 216 |
1. 47.4 (0.8) 2. 47.4 (0.9) 3. (1.6) 43.8 (0.8) |
Jaeger Master Screen | 1. 101 (0.9) 2. 70 (0.73) 3. 53.1 (1.6) 102.6 (1.4) |
MMEF all groups | 90% 70% 50% |
138 74 80 |
71 1 1 |
19 0 0 |
197 216 216 |
66 99 99 |
91 100 100 |
Global strategy: Joint Report of the NHLBI and WHO 1993 |
*For both groups.
ATS, American Thoracic Society; FEV1, forced expiratory volume in 1 s; FN, false negative; FP, false positive; GINA, Global Initiative for Asthma; ID, study identification (authors) country, research type; NHLBI, National Heart, Lung, and Blood Institute; NR, not reported; SA, small airways; Sen, sensitivity; Spc, specificity; TN, true negative; TP, true positive.